More than five million Americans live with Alzheimer's disease. Research coming out from the Alzheimer's Association Conference in Washington looks at an experimental drug, solanezumab. The treatment may attack the underlying cause and slow the devastating illness' progress. Dr. David Agus joins "CBS This Morning" to discuss the effects of the drug.
